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]Outbreaks can have devastating socio-economic and mental health impacts if the spread of disease is not
stopped. Particularly in the case of COVID-19 which has claimed thousands of lives across the globe, the
importance of rapid response to disease outbreaks is paramount. In the past, response to pandemics was
following very long licensing and development timeframes, whereas in the case of COVID-19 the response was
immediate while approval and manufacturing timeframes were much shorter. The global COVID-19 pandemic
has highlighted the important role that scalable and flexible manufacturing solutions play in enabling rapid
response to new disease outbreaks. In this unprecedent situation the industry joined forces and accelerated the
development of new vaccine candidates to rapidly respond to the pandemic. Following this the next hurdle was
to ensure that scaling up the production capacity to respond to the global immunization demand was feasible.
Indeed, manufacturing capacity often acts as a bottleneck in rapid development programs. Traditional
manufacturing processes are highly complex, require extensive process development efforts, and tend to suffer
from a lack of scalability to rapidly reach commercial scale capacity. Considering the short timelines, vaccines
are developed and scale-up at risk, with companies deploying manufacturing facilities at very early stage.
Therefore, it is important that manufacturers can rapidly adapt their existing equipment and facilities for
alternative drug candidates. This requires manufacturers to have facilities and equipment that are truly flexible
and can be adapted for different drug candidates and processes.
This is where platform technologies can play a major role. Advances in integrated and automated manufacturing
technologies result in cost-effective, scalable, and highly productive processes. Those technologies are
considered as flexible by design as they can accommodate various expression systems, vaccine applications
and capacity requirements. This presentation will focus on the breakthrough structured fixed-bed bioreactors
and an integrated and automated manufacturing platform that can enable cost-effective and flexible multiproduct
facilities with capacities of up to billions of vaccines per year in a reduced footprint and reduced capex.
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